πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12318375

Method of treatment with tradipitant

VANDA PHARMACEUTICALS INC. Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12319929

Compositions and methods for the treatment of Parkinson's disease

VOYAGER THERAPEUTICS, INC. Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12318356

Use of cannabinoids in the treatment of epilepsy

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED Β· Granted Tue Jun 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310992

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12311054

Compositions and methods of using propylene sulfide-based polymers for treatment of Chagas

Northwestern University Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310929

Use of rasagiline for the treatment of restless legs syndrome

TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310934

Methods of treatment of spontaneous preterm birth

The Regents of the University of California Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310965

Treatment of cancer utilizing an identified adenosine fingerprint

Arcus Biosciences, Inc. Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12311017

Identification of immunologically protective neo-epitopes for the treatment of cancers

UNIVERSITY OF CONNECTICUT Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12310986

Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxida

The Board of Regents of the University of Texas System Β· Granted Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12303724

Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematologica

Takeda Pharmaceutical Company Limited Β· Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12295929

Intravenous baclofen formulations and treatment methods

Regents of the University of Minnesota Β· Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290596

Compositions and methods for the treatment of opioid overdose

Indivior UK Limited Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12292445

Methods of selecting subjects for treatment with metabolomic modulators

The Regents of the University of California Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290538

Methods and products for treatment of gastrointestinal disorders

Finch Therapeutics Holdings LLC Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290551

Methods for imaging and treatment of somatostatin-receptor positive tumors

Corcept Therapeutics Incorporated Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291548

Compounds, compositions, and methods for the treatment of disease

Sperovie Biosciences, Inc. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290651

Devices and methods for the treatment of body surface disorders

Verrica Pharmaceuticals Inc. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291507

Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12286479

Treatment with anti-Ξ±4Ξ²7 antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12286630

Treatment methods for muscular dystrophy

Sarepta Therapeutics, Inc. Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12286402

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12285490

ASH1L degraders and methods of treatment therewith

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12285397

Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related co

OVID THERAPEUTICS INC. Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted